OSTX OSTX
Company Profile ↓Company Overview
OSTX (OSTX) is a publicly traded company listed on with a market capitalization of $59.38M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -7.51% |
| 6 Months: | +13.48% |
| 3 Months: | -7.51% |
| 1 Month: | +0.63% |
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)49.54 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 36.0% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | 5.00M | 4.84M | 6.88M | 11.99M | 10.17M |
| Operating Income | -1.05M | -1.52M | -622.21K | -630.23K | -779.80K | -2.44M | - | -5.00M | -4.84M | -6.88M | -11.99M | -10.17M |
| EBITDA | - | - | - | - | - | - | - | -3.88M | -4.42M | -6.75M | -13.34M | -10.20M |
| Interest Expense | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 75.34K |
| Pretax Income | - | - | - | - | - | - | - | -3.88M | -4.54M | -6.88M | -13.46M | -10.40M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -1.85M | -2.51M | -1.97M | -1.46M | -1.56M | -2.88M | - | -3.88M | -4.54M | -6.88M | -13.46M | -10.40M |
| Diluted EPS | - | -0.47 | -0.38 | -0.25 | -0.26 | -0.18 | - | -0.18 | -0.19 | -0.21 | - | -0.27 |
| R&D Expense | 753.78K | 992.90K | 454.50K | 361.81K | 396.57K | 1.21M | - | 1.31M | 2.50M | 3.76M | - | 7.35M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 4.45M | 4.34M | 6.81M | 28.71M |
| Operating Income | - | -4.45M | -4.34M | -6.81M | -28.71M |
| EBITDA | - | -4.45M | -4.34M | -6.83M | -28.39M |
| Interest Expense | - | 1.81M | 3.45M | 2.05M | 0 |
| Pretax Income | - | -6.25M | -7.79M | -8.88M | -28.75M |
| Tax Provision | - | - | - | - | - |
| Net Income | - | -6.25M | -7.79M | -8.88M | -28.75M |
| Diluted EPS | - | -0.32 | -0.38 | -1.28 | -0.98 |
| R&D Expense | - | - | 3.22M | 2.84M | 16.36M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 509.11K | 798.08K | 5.54M | 6.84M |
| Current Assets | - | 496.83K | 790.03K | 5.53M | 332.91K |
| Cash & Equivalents | - | 171.48K | 38.98K | 5.53M | 269.83K |
| Inventory | - | - | - | - | - |
| Receivables | 231.07K | 1.15K | 0 | - | - |
| Total Liabilities | - | 18.07M | 24.81M | 8.81M | 12.94M |
| Current Liabilities | - | 6.15M | 24.71M | 4.63M | 11.76M |
| Long Term Debt | 7.07M | 10.35M | - | - | - |
| Total Debt | 7.07M | 10.35M | 14.61M | - | - |
| Total Equity | - | -17.56M | -24.02M | -3.27M | -6.10M |
| Shares Outstanding | - | 20.60M | 20.60M | 20.87M | 37.11M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -3.79M | -3.01M | -7.28M | -14.24M |
| Investing Cash Flow | - | 230.88K | 1.15K | 0 | -466.42K |
| Financing Cash Flow | - | 3.65M | 2.87M | 12.78M | 9.44M |
| Capital Expenditure | -11.93K | - | - | - | -466.42K |
| Free Cash Flow | - | -3.79M | -3.01M | -7.28M | -14.70M |
| Net Change in Cash | - | 90.69K | -132.50K | 5.49M | -5.26M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | 35.6% | 32.4% | 271.9% | 471.7% |
| ROCE % | - | 78.9% | 18.2% | -747.6% | 582.9% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for OSTX
OS Therapies Inc SEC Filing (Jul 24, 2026) | OSTX ARS - Stock Titan
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxOTDJ0UnF5b0cxa2xabVNhMWoxS29aTnJHR0YxZGFkQ2RqNUY2QlZLcmo4NjFoMWsyRUhpUEVLbVljbDJnOGFHbF9NWTB6cE5vTjgxQ2poUDRWaHVZQ1R5aHQ3MjBFQVVFVm1DYlZLMVktTmxyU1pYc2pRSXRLcHBNY0paMjVsLXdISEJVUV…
OSTX|OS Therapies Inc|Price:1.535|Chg%:+0.015 - TradingKey
<a href="https://news.google.com/rss/articles/CBMiWkFVX3lxTE5Uel95QkVQbTRhQkpHQmJZLUY2bm1nWkUydjB5ZWthM2Q3SWZTQkNnYjFRR3lVMHl4RXVna1ZnUlp5S2h1S3NYMWdKU19aTWd2VnpKX3F3TjZKUQ?oc=5" target="_blank">OSTX|OS Therapies Inc|Price:1.535|Chg%:+0.015…
OST-HER2 osteosarcoma drug faces 2026 FDA and EMA decisions - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxNRkc3YlpDbVNReTJNTEtoYklCY1ROOHVNbUs2NzNVc292WW5EMEVHczdJX3YzVF9BMDllMTJqVWw1a1Ewd1RLWGowM3FXRnd3NEc1TGVuTloxbnVDUUU1UjJrWW5OS2VtbjVyR24tVlYyQ3VPYWNoLUdIMFEzalhtcnZ6WEtCQWxOeFRfMG…
OS Therapies Announces Filing Form S-1 of OS Animal Health Subsidiary - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMihwFBVV95cUxORm8wYWl0N0tYN3JqdzJBcUhHSDJqNTdyeW9DOURwX3Y1TGduWjFsUzJZeVZtazU4MW5EYUE5X0p5UE5aamEzanJ4QmU5dHZBQ1MtTWVwWEtDUHJwMnNZRGdVWEJyaXk3VWl1Ylh5TFAzV3loSXlwQlJkdEJ6b2ZNTzZWcjM1LVk?oc=5" …
OS Therapies Incorporated(NYSEAM:OSTX) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxNc2ZVel9JZWdOWUdZUjlfWF9tOEtwbVJHblJ0UlRtWnMzd19ZTFVLRDNEbkhzUC1NWUZrR1dwUmdZSlBOTG80MjlLcU5Hc0Y4ME1iRlJWTFNsbDU1MHV4bS12ZV9XazdDcmZtZG9UMktCcUJYOGM0M0xuRHFVQnV5a0VzeDdhS0l4alRHQl…
Roth MKM Initiates OS Therapies(OSTX.US) With Buy Rating, Announces Target Price $7 - Moomoo
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxNYW5xTG9EbU9URXBWdFM0X0F5SVFEVVljWEw5cURwdUt2S1pZdEktM2k4eEQ2QWRyLVlQN05WZjUzZVpjODFJUzhDMGg3VDRQSFQxS1BpQjVJSXY3WlVOTWN3cW9KVDZOYktrd1ZHMG1raTUxTU5QSVB4eEF2bzhhYUpWX2FhXzh5MmpfSF…
OSTX — Frequently Asked Questions
What is the current share price of OSTX?
As of 2026-08-05 17:25 PDT, OSTX trades at $1.60 on NASDAQ/NYSE. Its 52-week range is $1.16 to $2.50.
What is the market capitalisation of OSTX?
OSTX has a market capitalisation of $59.38M on NASDAQ/NYSE.
What is the P/E ratio of OSTX?
OSTX trades at a trailing price-to-earnings (P/E) ratio of -1.63. Its price-to-book (P/B) ratio is -9.74.
Is OSTX a good stock to buy?
This page provides a data-driven analysis of OSTX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.